20 articles
A phase II trial tests whether sunitinib retains activity in metastatic renal cell carcinoma after first-line immunotherapy resistance.
A phase I/II trial combining nivolumab, ipilimumab, and lurbinectedin for relapsed SCLC was terminated early, raising questions about feasibility.
Modified immune cells targeting GD2 protein demonstrated safety in treating aggressive childhood cancers like neuroblastoma and osteosarcoma.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
A Phase II NCI trial testing bintrafusp alfa in metastatic urothelial carcinoma was terminated after enrolling only 2 patients.
Phase 3 trial pits next-gen GnRH antagonist degarelix against standard goserelin in prostate cancer hormone suppression.
New study shows how analyzing fluid from lungs can detect cancer mutations and guide personalized treatment decisions.
A phase II trial tests whether 1Gy intestinal radiation can re-sensitize solid tumors that have stopped responding to immunotherapy.
Swiss researchers completed a 74-patient phase 2 trial exploring optimal dosing schedules for dual checkpoint blockade in metastatic renal cell carcinoma.
GSK's Phase 1/2 trial tests belantamab mafodotin paired with standard regimens in patients who failed prior myeloma therapy.
A completed French trial explores how gut and airway microbiota, blood, and sputum biomarkers relate to immunotherapy outcomes in metastatic NSCLC.
A completed Phase 2 trial explores whether low-dose continuous chemotherapy can boost immunotherapy efficacy in advanced lung cancer.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
Small trial tests innovative treatment IBI346 for blood cancer patients who didn't respond to standard therapies.
A phase I trial tests SD-101, nivolumab, and radiation together against metastatic pancreatic cancer that has stopped responding to chemo.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
A Phase 1/2 trial tests a custom cancer vaccine paired with checkpoint inhibitors in patients with advanced solid tumors.
